A comprehensive review of SHP2 and its role in cancer

MD Asmamaw, XJ Shi, LR Zhang, HM Liu - Cellular Oncology, 2022 - Springer
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application

X Yuan, H Bu, J Zhou, CY Yang… - Journal of medicinal …, 2020 - ACS Publications
SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

C Fedele, S Li, KW Teng, CJR Foster, D Peng… - Journal of Experimental …, 2020 - rupress.org
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy

Y Song, S Wang, M Zhao, X Yang… - Journal of medicinal …, 2022 - ACS Publications
The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery …

Targeting SHP2 as a promising strategy for cancer immunotherapy

Q Liu, J Qu, M Zhao, Q Xu, Y Sun - Pharmacological research, 2020 - Elsevier
Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) is a major phosphatase
involved in several cellular processes. In recent years, SHP2 has been the focus of …

Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy

J Pan, L Zhou, C Zhang, Q Xu, Y Sun - Signal transduction and targeted …, 2022 - nature.com
Inflammation is the common pathological basis of autoimmune diseases, metabolic
diseases, malignant tumors, and other major chronic diseases. Inflammation plays an …

[HTML][HTML] Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Z Song, M Wang, Y Ge, XP Chen, Z Xu, Y Sun… - … Pharmaceutica Sinica B, 2021 - Elsevier
Src homology containing protein tyrosine phosphatase 2 (SHP2) represents a noteworthy
target for various diseases, serving as a well-known oncogenic phosphatase in cancers. As …

Novel PROTACs for degradation of SHP2 protein

M Zheng, Y Liu, C Wu, K Yang, Q Wang, Y Zhou… - Bioorganic …, 2021 - Elsevier
Protein tyrosine phosphatase SHP2 is a member of PTPs family associated with cancer such
as leukemia, non-small cell lung cancer, breast cancer, and so on. SHP2 is a promising …

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers

D Shen, W Chen, J Zhu, G Wu, R Shen, M Xi… - European Journal of …, 2020 - Elsevier
Abstract Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2), encoded
by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing …

Discovery of novel Src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor …

M Liu, S Gao, T Liang, X Qiu, X Yang… - Journal of Medicinal …, 2022 - ACS Publications
Both Src homology-2 domain-containing phosphatase 2 (SHP2) and histone deacetylase
(HDAC) are important oncoproteins and potential immunomodulators. In this study, we first …